Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.43 |
| ▸ | RPTOR | Q8N122 | 5/20 | 0.43 |
| ▸ | MLST8 | Q9BVC4 | 5/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15807499 | 1.00 | MTOR (0.43) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL2147700 | 1.00 | MTOR (0.43) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL2147002 | 0.98 | MTOR (0.41) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL14298829 | 0.98 | MTOR (0.41) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL15026308 | 0.95 | MTOR (0.38) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL14246291 | 0.95 | MTOR (0.38) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL14298823 | 0.94 | MTOR (0.38) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL14299058 | 0.93 | MTOR (0.43) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL2148008 | 0.93 | MTOR (0.43) | MTORRPTORMLST8DGAT1GPR119 | |
| SCHEMBL2148294 | 0.93 | MTOR (0.43) | MTORRPTORMLST8DGAT1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736338-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2608668-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8901142-B2 | Fused tricyclic compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2736338-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2608668-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| WO-2013016164-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2012027234-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 5/4885 |
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 23/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | MTOR 1/4885RPTOR 4/4885MLST8 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.